Maarten van der Doelen

Appendices

Presentations

• VanderDoelenMJ , IsaacssonVelhoP, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, Van Helvert S, Kroeze LI, Van Oort IM, Gerritsen WR, Antonarakis ES, N. Mehra N. Overall survival using radium-223 in metastatic castrate-resistant prostate cancer patients with and without DNA damage repair defects. J Clin Oncol. 2020;38:6_ suppl, 121. Poster presentation at ASCO Genitourinary Cancers Symposium, San Francisco, CA, USA. 2020. • Van der DoelenMJ , Fransen van de Putte EE, Horenblas S, Heesakkers JPFA. Results of the York Mason procedure with or without concomitant graciloplasty to treat iatrogenic rectourethral fistulas. Eur Urol Suppl. 2019;18:e1700-e1701. Poster presentation at EAU annual congress, Barcelona, Spain. 2019. • Van der Doelen MJ, Mehra N, Van Oort IM, Heijmen L, Janssen MJR, Haberkorn U, Kratochwil C, Gerritsen WR. Clinical experience with PSMA labeled Actinium-225 radioligand therapy in end-stage metastatic castration-resistant prostate cancer patients. Eur Urol Suppl. 2018;17:e875-e876. Oral presentation at EAU annual congress, Copenhagen, Denmark. 2018. • Smits M, van der Doelen MJ , Westdorp H, van Oort IM, Sedelaar JPM, van der Heijden AG, Witjes JA, Schalken JA, de Vries J, Gerritsen WR, Gulley JL, Mehra N. Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastatic castration resistant prostate cancer. J Clin Oncol. 2018;36:6_suppl, 248. Poster presentation at ASCO Genitourinary Cancers Symposium, San Francisco, CA, USA. 2018. • Van der Doelen MJ , Mehra N, Van Oort IM, Heijmen L, Janssen MJR, Haberkorn U, Kratochwil C, Gerritsen WR. Clinical experience with PSMA labeled Actinium-225 radioligand therapy in end-stage metastatic castration-resistant prostate cancer patients. J Clin Oncol. 2018;36:6_suppl, 344. Poster presentation at ASCO Genitourinary Cancers Symposium, San Francisco, CA, USA. 2018. • Mehra N, van Riet J, Smits M, Westdorp H, Gorris M, van Ee T, van der Doelen MJ , van Oort IM, Sedelaar JPM, Textor J, Cuppen E, Grunberg K, Ligtenberg MJL, Zwart W, Bergman AM, van de Werken HJG, Schalken JA, de Vries IJM, Lolkema MP, GerritsenWR. In-depth assessment of metastatic prostate cancer with high tumour mutational burden. Ann Oncol. 2018;29(suppl_8): viii274. Poster presentation at ESMO Congress, Munich, Germany. 2018. • Van der Doelen MJ , Kuppen MCP, Jonker MA, Mehra N, Janssen MJR, Van Oort IM, Gerritsen WR. Real world lessons for optimal selection of patients with bone

A

251